BioSpace News Archive

Pharma and biotech laboratories performing high-throughput screening, high-content screening and molecular cell biology can now benefit from a series of new automated incubators and storage solutions that offer a large capacity, fast access and wide temperature range, while helping eliminate contamination issues in high-throughput environments.

ContraFect Corporation (Nasdaq: CFRX) a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the first quarter ended March 31, 2021.

Mind Medicine Inc., a leading psychedelic medicine biotech company, has announced its quarterly financial results for the quarter ended March 31, 2021.

Creative Medical Technology Holdings Inc., trading under ticker symbol CELZ, announced today receipt of detailed correspondence from the FDA regarding necessary modifications to IND #27375 for using ImmCelz® regenerative immunotherapy for the treatment of stroke.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (“MindMed” or the “Company”) is pleased to announce that it has appointed Dr. Sarah Y. Vinson as a director of the Company and a member of its audit committee, effective immediately.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced financial results for the three months ended March 31, 2021, and provided an update on clinical development programs with GEN-1, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase I/II clinical development for the localized treatment of ovarian cancer, and ThermoDox

Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that Dr. Roly Foulkes, Chief Scientific Officer, will present information relating to the Company’s lead autoimmune and allergic disease drug candidates, ’1805 and ‘1104, during the 3rd Annual Treg Directed Therapies Summit

Coya Therapeutics, Inc., (Coya), today announced that Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics, will present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit being held virtually on May 21, 2021.

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from a preclinical study of KER-012

Cardinal Health announced that it is sending an irrevocable notice of early redemption to the holders of all of the Company’s 3.200% notes due June 2022 that are outstanding as of the early redemption date and $262,442,000 in aggregate principal amount of the Company’s 2.616% notes due June 2022.